Please try another search
For the fiscal year ended 31 December 2021, Kinarus Therapeutics Holding AG revenues decreased from SF4.1M to SF0K. Net loss increased from SF7K to SF143K. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Financial income decrease of 74% to SF280K (income), FX Transaction decrease from SF23K (income) to SF0K.
Period Ending: | Dec 31, 2021 | Jun 30, 2021 | Dec 31, 2020 | Jun 30, 2020 |
---|---|---|---|---|
Total Revenue | 0 | 0 | 4.11 | 4.24 |
Gross Profit | 0 | 0.52 | 0.54 | |
Operating Income | -0.17 | -0.24 | -1.1 | -0.91 |
Net Income | -0.18 | 0.03 | -0.01 | 0.19 |
Period Ending: | Dec 31, 2021 | Jun 30, 2021 | Dec 31, 2020 | Jun 30, 2020 |
---|---|---|---|---|
Total Assets | 0.14 | 0.18 | 0.13 | 0.21 |
Total Liabilities | 0.54 | 0.41 | 0.38 | 0.28 |
Total Equity | -0.4 | -0.22 | -0.26 | -0.06 |
Period Ending: | Dec 31, 2021 | Jun 30, 2021 | Dec 31, 2020 | Jun 30, 2020 |
---|---|---|---|---|
Period Length: | 0 Months | 0 Months | 12 Months | 6 Months |
Cash From Operating Activities | -0.36 | -0.13 | -0.38 | -0.06 |
Cash From Investing Activities | 0 | 0 | -0.9 | -0.9 |
Cash From Financing Activities | 0.42 | 0.23 | 0.52 | 0.32 |
Net Change in Cash | 0.06 | 0.11 | -0.82 | -0.71 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review